Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis

Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis

Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse e...

Full description

Bibliographic Details
Main Authors: Go, Seong Woo, Kim, Boo Kyeong, Lee, Sung Hak, Kim, Tae-Jung, Huh, Joo Yeon, Lee, Jong Min, Hah, Jick Hwan, Kim, Dong Whi, Cho, Min Jung, Kim, Tae Wan, Kang, Ji Young
Format: Online
Language:English
Published: The Korean Academy of Tuberculosis and Respiratory Diseases 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884114/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884114/

Similar Items